DB:2VJ

Stock Analysis Report

Executive Summary

Ascletis Pharma Inc., a biotechnology company, engages in the research and development, manufacturing, marketing, and sale of pharmaceutical products in the People’s Republic of China and internationally.

Snowflake

Fundamentals

Flawless balance sheet with high growth potential.

Share Price & News

How has Ascletis Pharma's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: 2VJ's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

7.8%

2VJ

-2.3%

DE Biotechs

0.03%

DE Market


1 Year Return

-45.5%

2VJ

-6.9%

DE Biotechs

9.9%

DE Market

Return vs Industry: 2VJ underperformed the German Biotechs industry which returned -6.9% over the past year.

Return vs Market: 2VJ underperformed the German Market which returned 9.9% over the past year.


Shareholder returns

2VJIndustryMarket
7 Day7.8%-2.3%0.03%
30 Day47.6%-3.1%4.4%
90 Day10.7%-9.6%13.6%
1 Year-45.5%-45.5%-6.7%-6.9%13.4%9.9%
3 Yearn/a52.7%50.8%25.6%14.6%
5 Yearn/a5.0%2.7%36.9%18.2%

Price Volatility Vs. Market

How volatile is Ascletis Pharma's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Ascletis Pharma undervalued compared to its fair value and its price relative to the market?

1.26x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: 2VJ (€0.5) is trading above our estimate of fair value (€0)

Significantly Below Fair Value: 2VJ is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: 2VJ is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: 2VJ is unprofitable, so we can't compare its PE Ratio to the German market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate 2VJ's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: 2VJ is good value based on its PB Ratio (1.3x) compared to the DE Biotechs industry average (3.1x).


Next Steps

Future Growth

How is Ascletis Pharma forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?

113.9%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: 2VJ is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (0.2%).

Earnings vs Market: 2VJ is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: 2VJ's is expected to become profitable in the next 3 years.

Revenue vs Market: 2VJ's revenue (67.5% per year) is forecast to grow faster than the German market (4.8% per year).

High Growth Revenue: 2VJ's revenue (67.5% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: 2VJ's Return on Equity is forecast to be low in 3 years time (7.4%).


Next Steps

Past Performance

How has Ascletis Pharma performed over the past 5 years?

-3682.1%

Last years earnings growth


Earnings and Revenue History

Quality Earnings: 2VJ has a high level of non-cash earnings.

Growing Profit Margin: 2VJ's current net profit margins (-70%) are lower than last year (-1.7%).


Past Earnings Growth Analysis

Earnings Trend: Insufficient data to determine if 2VJ's year-on-year earnings growth rate was positive over the past 5 years.

Accelerating Growth: Unable to compare 2VJ's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 2VJ is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (5.4%).


Return on Equity

High ROE: 2VJ has a negative Return on Equity (-2.62%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Next Steps

Financial Health

How is Ascletis Pharma's financial position?


Financial Position Analysis

Short Term Liabilities: 2VJ's short term assets (CN¥3.2B) exceeds its short term liabilities (CN¥72.7M)

Long Term Liabilities: 2VJ's short term assets (3.2B) exceeds its long term liabilities (9.9M)


Debt to Equity History and Analysis

Debt Level: 2VJ is debt free.

Reducing Debt: 2VJ has not had any debt for past 5 years.


Balance Sheet

Inventory Level: 2VJ has a low level of unsold assets or inventory.

Debt Coverage by Assets: Insufficient data to determine if 2VJ's debt is covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: 2VJ has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: 2VJ has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of -11% each year


Next Steps

Dividend

What is Ascletis Pharma's current dividend yield, its reliability and sustainability?

0.31%

Forecast Dividend Yield


Dividend Yield vs Market

companyn/amarketbottom25%1.3%markettop25%3.7%industryaverage1.1%forecastin3Years0.3%

Current dividend yield vs market & industry

Notable Dividend: Unable to evaluate 2VJ's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate 2VJ's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if 2VJ's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if 2VJ's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of 2VJ's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

What is the CEO of Ascletis Pharma's salary, the management and board of directors tenure and is there insider trading?

2.3yrs

Average management tenure


CEO

Jinzi Jason Wu (56yo)

6.6yrs

Tenure

0

Dr. Jinzi Jason Wu Ph.D, is a Founder of Ascletis Pharma Inc and has been its Chairman March 30, 2018 and has been its CEO since April 2013. He has over 12 years experience in research and development in b ...


Management Age and Tenure

2.3yrs

Average Tenure

51yo

Average Age

Experienced Management: 2VJ's management team is considered experienced (2.3 years average tenure).


Board Age and Tenure

1.6yrs

Average Tenure

46yo

Average Age

Experienced Board: 2VJ's board of directors are not considered experienced ( 1.6 years average tenure), which suggests a new board.


Insider Trading

Insider Buying: 2VJ insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

BuyCN¥119,41917 Oct 19
Jinzi Jason Wu
EntityIndividual
Role
Chief Executive Officer
Founder
Shares344,000
Max PriceCN¥0.35
BuyCN¥102,39817 Oct 19
Jinzi Jason Wu
EntityIndividual
Role
Chief Executive Officer
Founder
Shares296,000
Max PriceCN¥0.35
BuyCN¥182,57717 Oct 19
Jinzi Jason Wu
EntityIndividual
Role
Chief Executive Officer
Founder
Shares529,000
Max PriceCN¥0.35
BuyCN¥399,23917 Oct 19
Jinzi Jason Wu
EntityIndividual
Role
Chief Executive Officer
Founder
Shares1,142,000
Max PriceCN¥0.35
SellCN¥5,415,56419 Jun 19
CBC Investment Fifteen Limited
EntityCompany
Shares7,228,958
Max PriceCN¥0.75
SellCN¥7,698,72818 Jun 19
CBC Investment Fifteen Limited
EntityCompany
Shares10,327,083
Max PriceCN¥0.75
SellCN¥11,230,77312 Jun 19
CBC Investment Twelve Limited
EntityCompany
Shares15,701,994
Max PriceCN¥0.72
SellCN¥107,87519 Mar 19
GIC Pte. Ltd.
EntityCompany
Shares136,000
Max PriceCN¥0.79
SellCN¥40,39413 Mar 19
Citigroup Inc.,Banking and Securities Investments
EntityCompany
Shares45,000
Max PriceCN¥0.90

Ownership Breakdown

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 64.1%.


Management Team

  • Jinzi Jason Wu (56yo)

    Founder

    • Tenure: 6.6yrs
  • Judy Wu (45yo)

    VP of Operations & Executive Director

    • Tenure: 1.7yrs
  • Lok Yim

    Company Secretary

    • Tenure: 1.4yrs
  • Helen Yan (49yo)

    VP & Director of Sales

    • Tenure: 3yrs
  • Kristjan Gudmundsson (51yo)

    Senior Consultant & Head of Discovery

    • Tenure: 6.5yrs
  • George Hill (69yo)

    Senior Consultant & Chief Medical Advisor

    • Tenure: 1.7yrs
  • Handan He

    Chief Scientific Officer

    • Tenure: 0.08yrs

Board Members

  • Jinzi Jason Wu (56yo)

    Founder

    • Tenure: 6.6yrs
  • Jiong Gu (47yo)

    Independent Non-Executive Director

    • Tenure: 1.6yrs
  • Judy Wu (45yo)

    VP of Operations & Executive Director

    • Tenure: 1.7yrs
  • Ru Rong Ji (55yo)

    Independent Non-Executive Director

    • Tenure: 1.6yrs
  • Yizhen Wei (44yo)

    Independent Non-Executive Director

    • Tenure: 1.6yrs
  • Lin Hua (45yo)

    Independent Non-Executive Director

    • Tenure: 1.6yrs
  • Lingjie Jiang

    Senior Supervisor

    • Tenure: 0yrs

Company Information

Ascletis Pharma Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Ascletis Pharma Inc.
  • Ticker: 2VJ
  • Exchange: DB
  • Founded: 2014
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: HK$5.043b
  • Listing Market Cap: HK$583.289m
  • Shares outstanding: 1.12b
  • Website: https://www.ascletis.com

Number of Employees


Location

  • Ascletis Pharma Inc.
  • Building 3
  • 12th Floor
  • Hangzhou
  • Zhejiang Province
  • China

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
1672SEHK (The Stock Exchange of Hong Kong Ltd.)YesOrdinary SharesHKHKDAug 2018
2VJDB (Deutsche Boerse AG)YesOrdinary SharesDEEURAug 2018

Biography

Ascletis Pharma Inc., a biotechnology company, engages in the research and development, manufacturing, marketing, and sale of pharmaceutical products in the People’s Republic of China and internationally.  ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/11/16 21:46
End of Day Share Price2019/11/15 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.